20/20 BIOLABS INC
AIDXNASDAQ🏆 #3728 by market capUS Equity
$0.44▼ $0.01 (−2.84%)
Live1h—
24h▼ 2.8%
7d▼ 2.8%
14d▼ 16.9%
30d▼ 23.9%
1y—
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
47
Weak
Trading Snapshot
- Day Range
- $0.43 – $0.45
- 52-Week Range
- $0.40 – $50.00
- Volume
- $2.00B
- Avg Volume
- $2.24B
- Shares Outstanding
- 12.3M
- Next Earnings
- Sep 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $581,019
- Last Q Revenue
- $131,178
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own AIDX
- ✓High-growth profile — revenue up +29.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$581,019▲ +24.0% YoY
Gross Margin (TTM)
78.7%▲ +3.4% YoY
Operating Income (TTM)
$156,875▲ +24.0% YoY
Free Cash Flow (TTM)
$113,299▲ +24.0% YoY
About 20/20 BIOLABS INC
A company profile for 20/20 BIOLABS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
47/100
Analyst Price Target
ⓘAverage Target
$0.55
▲ +24.8% Upside
High Target$0.62
Low Target$0.47
Based on 28 analysts
Latest News & Updates
🚀
CNBC·2h ago
20/20 BIOLABS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift AIDX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
20/20 BIOLABS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.